MannKind presents new Afrezza pediatric efficacy data from INHALE-1 study at ADA 2026

Mannkind

Mannkind

MNKD

0.00
  • MannKind flagged new Afrezza clinical and real-world analyses slated for presentation at the ADA 2026 meeting on June 5-8.
  • Data focus on pediatric use, pregnancy, and use alongside automated insulin delivery systems, aiming to support broader adoption and new patient segments.
  • Late-breaking results comparing Afrezza with rapid-acting insulin analogs are scheduled for June 7, with outcomes positioned around efficacy, safety, and patient experience.
  • The FDA decision date for Afrezza in children and adolescents ages 4-17 is set for May 29, 2026, a key near-term catalyst.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605270905PRIMZONEFULLFEED9727046) on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.